An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and ...

Alston & Bird allege their client has suffered more than $1 billion in lost sales from being unable to manufacture a biosimilar product in the United States to compete with Amgen's blockbuster Enbrel ...

Alston & Bird on behalf of a rival pharma company alleges Amgen prevented would-be competitors from entering the U.S. product market for etanercept in violation of the Sherman Act. Representing ...

Sandoz has filed an antitrust lawsuit in the US against Amgen, challenging alleged anti-competitive practices surrounding the biologic blockbuster Enbrel (etanercept). Filed at the US District Court ...

(Reuters) -Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the United States against Amgen over the alleged entrenchment of the market position of its ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules <li /> Company aims to accelerate access to much-needed biosimi ...

Etanercept is a biologic medicine used to treat a range of disabling inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors ...

Sandoz filed an antitrust lawsuit in the US District Court for the Eastern District of Virginia against Amgen for extending and entrenching the dominant market position of Enbrel (etanercept), a ...

Etanercept is a biologic medicine used to treat a range of disabling inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors ...

Etanercept is a biologic medicine used to treat a range of disabling inflammatory diseases. Sandoz alleges that Amgen blocked competition from more cost-effective biosimilar competitors, including ...